Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a natural hormone help tame a common heart rhythm disorder?

NCT ID NCT07359872

Disease control Sponsor: Deeptankar DeMazumder Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tests whether relaxin, a natural hormone given as a daily injection, can reduce the burden of atrial fibrillation (AF) in 208 veterans who have not responded to standard medications and are scheduled for catheter ablation. The study aims to see if relaxin can counteract harmful electrical changes in the heart caused by oxidative stress, potentially lowering AF recurrence after the procedure. It is a Phase 1/2 study, meaning it is primarily evaluating safety and early effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Relaxin (a naturally occurring hormone given as a daily injection)
What this could lead to
If it works, this could point toward a new treatment to reduce atrial fibrillation recurrence after standard ablation procedures.
What could go wrong
This is an early Phase 1/2 trial with only 208 participants, so results may not apply broadly. The treatment is still experimental and may not prove effective or safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 208 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Diagnosed with AF and scheduled for elective catheter ablation for AF Exclusion Criteria: * Enrollment in another Greater than Minimal Risk Study * Pregnant, nursing, or sexually active females not using birth control or having been surgically sterilized * Females who plan to become pregnant during the trial period * Patients diagnosed with "permanent" AF, complete heart block, or a reversible cause of AF (e.g., transient thyrotoxicosis) * Patients that require antiarrhythmic medication to started or continued during and after the ablation procedure. * Patients unable to tolerate Relaxin therapy or unable or unwilling to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ablation of atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac atrial fibrillation cardiac rhythm disease heart failure stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ablation of atrial fibrillation Arrhythmia Atrial fibrillation (AF) Catheter ablation Heart failure Major cardiovascular event Oxidative stress Stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.